Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-399

Overview: In this episode, we look at a new study showing increased probability of survival for patients with Alzheimer disease (AD) who take donepezil and memantine together. We review current treatments for AD and address common hesitations in prescribing dual pharmacotherapy, providing vital insights for primary care clinicians.

Episode resource links:

• Yaghmaei, E., Lu, H., Ehwerhemuepha, L. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients.Commun Med 4, 99 (2024). https://doi.org/10.1038/s43856-024-00527-6
• Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299.

Guest: Jillian Joseph, MPAS, PA-C

Music Credit: Richard Onorato

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com

Credits: 0.50 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/Podcast/ask-the-expert-about-pain-management

Overview:

In this podcast, Dr. Katherine Galluzzi answers several of the frequently asked questions regarding pain management, such as the use of NSAIDs in patients with cardiovascular disease, the effects of long-term opioid therapy, practical approaches to initiating buprenorphine, and whether or not a Patient Provider Agreement is necessary for patients in hospice care.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-398

Overview: Low back pain is the leading cause of years lived with disability, with approximately 70% of individuals experiencing a recurrence within 12 months following recovery from an episode. Clinicians are poised to play a crucial role in encouraging patients to incorporate walking to prevent recurrences of low back pain.

Episode resource links:

• Pocovi NC, Lin CC, French SD, Graham PL, van Dongen JM, Latimer J, Merom D, Tiedemann A, Maher CG, Clavisi O, Tong SYK, Hancock MJ. Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack): a randomised controlled trial. Lancet. 2024 Jun 19:S0140-6736(24)00755-4. PMID: 38908392.

Guest: Alan M. Ehrlich, MD, FAAFP

Music Credit: Richard Onorato

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com